ResMed clears a fresh 52-week high, shares extend their Nasdaq run

ResMed adds another technical milestone as its sleep-therapy stock trades at a new 52-week high on Nasdaq. The move comes after recent analyst adjustments and ahead of the company’s next earnings update, keeping the sleep-apnea specialist in focus for global investors.

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 21:04.

ResMed Inc (AU000000RMD6) continues to attract attention after its shares reached a fresh 52-week high on Nasdaq this week. The medical-device maker for sleep-disordered breathing benefits from ongoing demand for sleep-apnea treatment and remains a notable health-tech name alongside peers such as Philips and Fisher & Paykel Healthcare, based on recent sector coverage.

ResMed technicals and recent highs

ResMed shares trade on Nasdaq under the ticker RMD, and the stock has recently pushed to a new 52-week high, with the level supported by global quote services that show the move against prior ranges. Market data providers such as Nasdaq and TradingView document the higher band, where ResMed now trades in the upper end of its one-year corridor compared with levels seen after last year’s earnings releases.

The new high comes against a broader backdrop of mixed US indices, with the S&P 500 and Nasdaq 100 trading slightly lower today while some health-care names show relative resilience. This technical setup places ResMed in a stronger relative-position than several diversified medtech peers, with the stock’s momentum contrasting more muted moves in parts of the sector, according to overview pages on platforms like Barchart that highlight index performances and sector slices.

Analyst views and earnings calendar

Analyst consensus compiled on portals such as MarketScreener and similar aggregators indicates that a majority of covering houses rate ResMed stock Buy or Outperform, and several target-price updates over recent months reflect improving sentiment after prior quarters of earnings growth and margin development. These analyst snapshots place ResMed alongside global medtech players like Medtronic and Boston Scientific in terms of coverage depth, with research from firms including UBS and Goldman Sachs forming part of the broader view on the stock.

ResMed’s investor relations calendar on its own website outlines upcoming events, including the next quarterly earnings release and conference calls where management will update on device volumes, software revenue and regional trends. The latest quarterly report, available via the company’s filings, detailed growth in masks and devices and highlighted increasing contributions from its cloud-based digital platform, elements that analysts often cite when adjusting their models. The combination of steady fundamental updates and visible dates on the calendar helps explain why the shares remain closely followed around reporting periods.

What the company sells

ResMed earns most of its revenue from devices and software for treating sleep-disordered breathing, especially obstructive sleep apnea. Its portfolio includes CPAP machines, masks and accessories, as well as digital health solutions that monitor usage and support physicians and sleep clinics in managing patient therapy.

Where the stock trades today

ResMed shares currently trade on Nasdaq under the ticker RMD, with the latest available quotes showing the stock in the upper part of its 52-week range; market data pages provide the precise price and timestamp for investors tracking intraday movements.

ResMed Inc at a glance

• Company: ResMed Inc
• ISIN: AU000000RMD6
• WKN: 895663
• Ticker: RMD
• Trading venue: Nasdaq
• Price (as of 2026-06-25, 19:00): [latest quote] USD
• Market cap: [current market cap] USD (as of 2026-06-25)
• Sector / industry: Health Care Equipment & Supplies
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.